Scollr summary
What this paper is about
A narrative review provides clinicians with an overview of how to manage patients with ATTRv-CM and their families and concludes that comprehensive genetic and cascade screening strategies are essential for early identification and optimal management of ATTR-CM.
Full abstract
Read the full abstract
With increasing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) as a cause of heart failure and the availability of disease-modifying therapies, the importance of early diagnosis has grown. Consequently, greater emphasis has been placed on genetic testing and family screening to identify individuals with variant transthyretin amyloidosis (ATTRv) who are at risk of developing ATTRv cardiomyopathy (ATTRv-CM). To identify individuals with a genetic predisposition to the disease, all individuals with ATTR-CM should undergo genetic testing with subsequent cascade genetic testing in relatives when a genetic variant is identified. In asymptomatic pathogenic/likely pathogenic (P/LP) transthyretin (TTR) variant carriers, structured follow-up is recommended to enable early diagnosis, allowing timely initiation of treatment. Additionally, systematic family screening protocols may also help identify and detect ATTR-CM in general, including wild-type ATTR-CM.In conclusion, this narrative review provides clinicians with an overview of how to manage patients with ATTRv-CM and their families. Indeed, comprehensive genetic and cascade screening strategies are essential for early identification and optimal management of ATTR-CM. Future perspectives include refinement of risk stratification, optimization of diagnostic and screening pathways, improved timing of treatment initiation, and addressing health inequalities to ensure equitable access to care.
Direct answer
What can I do from this paper page?
Use this page to scan "Family screening and genetic testing in transthyretin cardiac amyloidosis" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Amyloidosis: Diagnosis, Treatment, Outcomes research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Kieviet2026Family,
title = {Family screening and genetic testing in transthyretin cardiac amyloidosis},
author = {Leendert C. Kieviet and J. Peter van Tintelen and Steven A. Muller and Peter-Paul M. Zwetsloot and Michelle Michels and Christian Knackstedt and Peter van der Meer and Manon G. van der Meer and Laura M.G. Meems and Paul A. van der Zwaag and Marish I. F. J. Oerlemans and Hans L. A. Nienhuis},
journal = {Netherlands Heart Journal},
year = {2026},
doi = {10.1007/s12471-026-02088-w},
url = {https://doi.org/10.1007/s12471-026-02088-w}
}
FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Amyloidosis: Diagnosis, Treatment, Outcomes research papers?
Follow Amyloidosis: Diagnosis, Treatment, Outcomes research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Family screening and genetic testing in transthyretin cardiac amyloidosis. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app